A Khavinson bioregulator peptide for cerebral cortex function — studied for cognitive preservation in aging.
Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It is designed as a bioregulator of the cerebral cortex — following the same tissue-specific peptide bioregulation framework as Epithalon (pineal), Thymalin (thymus), and Pinealon (pineal/brain).
According to the Khavinson bioregulator theory, short peptides (2-4 amino acids) derived from specific tissues can enter cells, interact with DNA, and normalize gene expression patterns disrupted by aging or disease. Cortagen is proposed to restore cortical neuron function by regulating genes involved in neuroprotection, synaptic plasticity, and neurotransmitter metabolism.
Like other Khavinson peptides, Cortagen has been studied primarily at Russian institutions with limited independent Western validation. The theoretical framework is compelling but the evidence base is narrow.
Russian research shows Cortagen improves cognitive function in aging animal models, enhances synaptic transmission, and protects cortical neurons from hypoxic damage. Cell culture studies suggest regulation of gene expression in neural tissue.
Clinical observations from Russian practice suggest cognitive improvements in elderly patients receiving Cortagen as part of comprehensive bioregulator protocols. Independent peer-reviewed Western data is absent.
📚 Key Reference: PMID: 15637758 (Cortagen research)
No significant adverse events reported. Small peptide with low toxicity potential. Limited data. Consult your provider.
NOT FDA-approved. Research use only. Part of Khavinson bioregulator system.